TURN-KEY

DRUG DISCOVERY

  Aligning R&D with business and IP 

BUILT

BY INNOVATORS 

FOR INNOVATORS

Dalriada’s Turn-Key Drug Discovery model is specifically designed to provide ultimate support for semi-virtual lean biotechs developing small molecule therapies. 

We uniquely integrate internal R&D, end-to-end program management, business and IP support to unlock the most rapid and agile program execution and ultimately the fastest route to the clinic.

We focus on value building for each client and partner and conduct all programs with an R&D-to-milestone approach. Drawing experience from Pharma, Biotech, VC, and Academia, Dalriada’s team equally understands both the science and business needs, which allows for a seamless collaboration with the biotech client or a fully autonomous project execution.

Expert,

High-performance

R&D Teams

 
 

THREE PILLARS

OF TURN-KEY   

MODEL

1

2

3

Through unique integration of R&D, business and IP, we unlock the most agile program execution and rapid advancement of the asset

End-to-End Program Design and  Management

  • Expanding and jump-starting product pipelines

  • Program development

  • Data room and due diligence management

  • R&D out-sourcing management

  • Attracting KOLs and consultants

Business and IP Support

  • IP strategy/searches

  • Industry Positioning/Product Roadmap

  • Investment, partnership and licensing consulting

  • Support in company building

Internal Top 
Quality R&D

  • Accelerated hit-to-lead and lead optimization through chemistry-biology integration

  • Custom assay development
    for even the most innovative projects:

  • MedChem

  • In vitro pharmacology

  • Cell Biology

  • PK / ADME

OUR TRACK RECORD

Created a high-value pipeline

for multi-billion dollar company

 

WHY PARTNER

WITH US

Proprietary cascade

for targeted covalent

inhibitors discovery

and development

Most Rapid and Agile Program Execution

  • Focused teams built for each project within <2 weeks
     

  • Internal integrated chemistry-biology R&D significantly accelerates the
    hit-to-lead and lead optimization cycles
     

  • Shift the team size and composition any time as the project advances or expands

Accelerated

Value Building

IP-focused Approach

  • Ongoing Pharma, VC, and biotech
    insight into each project

     

  • R&D-to-milestone approach – from program planning to passing due diligence
     

  • Jump-starting and expanding pipelines

  • Scientific team trained
    by top legal firms

     

  • Experience with conservative and highly aggressive IP strategies

Customized Solution

for Every Project

Innovation-driven

Autonomous

Project Execution

  • Dedicated R&D-business-IP team built for each project
     

  • Development of custom programs and screening cascades tailored specifically
    to the project and business needs

  • Up-to-date with science
     

  • Custom assay development for most innovative projects
     

  • Monitoring and adapting to recent industry developments
     

  • Implementing break-through innovation

  • Projects executed fully
    autonomously by Dalriada or in a seamless collaboration with a client 

 

TOP

STANDARDS

 
 

OUR EXPERTISE

Small molecule therapeutics

Discovery to

IND-enabling

Kinase 
Inhibitors

Proprietary Cascade

for Targeted Covalent Inhibitors

Protein Degraders

Protein-protein Interaction

Inhibitors

GPCRs

 

OUR CLIENTS

1
11
9
2
6
10
12
8
7
4
5
13
1
11
9
2
6
10
12
8
7
4
5
13

VC-backed

Start-ups

Aggressive milestones

Driving innovation

Public Pharma Companies

Small and

Medium Biotechs

Accelerated program

advancement 

Academic SPIN-OUTS

Company-building
support

Translational

Academic Groups

Integrated support

R&D-Business-IP

Project go/no-go

decisions

Commercialization-

focused NFPs

 
 

CONTACT US

  • White LinkedIn Icon
  • White Twitter Icon

Toronto,

Canada